Literature DB >> 30745309

Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19.

Sandhya Devarajan1, Irene Moon1, Ming-Fen Ho1, Nicholas B Larson1, Drew R Neavin1, Ann M Moyer1, John L Black1, Suzette J Bielinski1, Steven E Scherer1, Liewei Wang1, Richard M Weinshilboum1, Joel M Reid2.   

Abstract

CYP2C9 and CYP2C19 are highly polymorphic pharmacogenes; however, clinically actionable genetic variability in drug metabolism due to these genes has been limited to a few common alleles. The identification and functional characterization of less-common open reading frame sequence variation might help to individualize therapy with drugs that are substrates for the enzymes encoded by these genes. The present study identified seven uncharacterized variants each in CYP2C9 and CYP2C19 using next-generation sequence data for 1013 subjects, and functionally characterized the encoded proteins. Constructs were created and transiently expressed in COS-1 cells for the assay of protein concentration and enzyme activities using fluorometric substrates and liquid chromatography- tandem mass spectrometry with tolbutamide (CYP2C9) and (S)-mephenytoin (CYP2C19) as prototypic substrates. The results were compared with the SIFT, Polyphen, and Provean functional prediction software programs. Cytochrome P450 oxidoreductase (CPR) activities were also determined. Positive correlations were observed between protein content and fluorometric enzyme activity for variants of CYP2C9 (P < 0.05) and CYP2C19 (P < 0.0005). However, CYP2C9 709G>C and CYP2C19 65A>G activities were much lower than predicted based on protein content. Substrate intrinsic clearance values for CYP2C9 218C>T, 343A>C, and CYP2C19 337G>A, 518C>T, 556C>T, and 557G>A were less than 25% of wild-type allozymes. CPR activity levels were similar for all variants. In summary, sequencing of CYP2C9 and CYP2C19 in 1013 subjects identified low-frequency variants that had not previously been functionally characterized. In silico predictions were not always consistent with functional assay results. These observations emphasize the need for high-throughput methods for pharmacogene variant mutagenesis and functional characterization.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Year:  2019        PMID: 30745309      PMCID: PMC6423619          DOI: 10.1124/dmd.118.084269

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  53 in total

1.  Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.

Authors:  D M Stresser; A P Blanchard; S D Turner; J C Erve; A A Dandeneau; V P Miller; C L Crespi
Journal:  Drug Metab Dispos       Date:  2000-12       Impact factor: 3.922

2.  In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population.

Authors:  Guo-Xin Hu; Pei-Pei Pan; Zeng-Shou Wang; Li-Ping Yang; Da-Peng Dai; Shuang-Hu Wang; Guang-Hui Zhu; Xiang-Jun Qiu; Tao Xu; Jun Luo; Qing-Quan Lian; Ren-Shan Ge; Jian-Ping Cai
Journal:  Drug Metab Dispos       Date:  2015-01-22       Impact factor: 3.922

3.  Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism.

Authors:  I Kariv; M P Fereshteh; K R Oldenburg
Journal:  J Biomol Screen       Date:  2001-04

4.  Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.

Authors:  Hiroshi Yamazaki; Mami Nakamura; Tomoko Komatsu; Katsuhiro Ohyama; Naoya Hatanaka; Satoru Asahi; Noriaki Shimada; F Peter Guengerich; Tsutomu Shimada; Miki Nakajima; Tsuyoshi Yokoi
Journal:  Protein Expr Purif       Date:  2002-04       Impact factor: 1.650

5.  Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system.

Authors:  Liewei Wang; Vivien C Yee; Richard M Weinshilboum
Journal:  Biochem Biophys Res Commun       Date:  2004-12-10       Impact factor: 3.575

6.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

7.  Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics.

Authors:  Yuan Ji; Irene Moon; Jelena Zlatkovic; Oreste E Salavaggione; Bianca A Thomae; Bruce W Eckloff; Eric D Wieben; Daniel J Schaid; Richard M Weinshilboum
Journal:  J Pharmacol Exp Ther       Date:  2007-05-11       Impact factor: 4.030

8.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

9.  Functional characterization of 32 CYP2C9 allelic variants.

Authors:  Y Niinuma; T Saito; M Takahashi; C Tsukada; Mi Ito; N Hirasawa; M Hiratsuka
Journal:  Pharmacogenomics J       Date:  2013-06-11       Impact factor: 3.550

10.  Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes.

Authors:  Duan Liu; Ming-Fen Ho; Daniel J Schaid; Steven E Scherer; Krishna Kalari; Mohan Liu; Joanna Biernacka; Vivien Yee; Jared Evans; Erin Carlson; Matthew P Goetz; Michiaki Kubo; D Lawrence Wickerham; Liewei Wang; James N Ingle; Richard M Weinshilboum
Journal:  NPJ Breast Cancer       Date:  2017-08-21
View more
  8 in total

1.  Functional characterization of the chlorzoxazone 6-hydroxylation activity of human cytochrome P450 2E1 allelic variants in Han Chinese.

Authors:  Ting Wang; Huihui Du; Jingsong Ma; Lu Shen; Muyun Wei; Xianglong Zhao; Luan Chen; Mo Li; Guorong Li; Qinghe Xing; Lin He; Shengying Qin
Journal:  PeerJ       Date:  2020-07-31       Impact factor: 2.984

Review 2.  Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare.

Authors:  Jyothsna Giri; Ann M Moyer; Suzette J Bielinski; Pedro J Caraballo
Journal:  Pharmgenomics Pers Med       Date:  2019-10-30

3.  Variation in Actionable Pharmacogenetic Markers in Natives and Mestizos From Mexico.

Authors:  Vanessa Gonzalez-Covarrubias; Marlet Morales-Franco; Omar F Cruz-Correa; Angélica Martínez-Hernández; Humberto García-Ortíz; Francisco Barajas-Olmos; Alma Delia Genis-Mendoza; José Jaime Martínez-Magaña; Humberto Nicolini; Lorena Orozco; Xavier Soberón
Journal:  Front Pharmacol       Date:  2019-10-10       Impact factor: 5.810

4.  SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function.

Authors:  Lingxin Zhang; Vivekananda Sarangi; Ming-Fen Ho; Irene Moon; Krishna R Kalari; Liewei Wang; Richard M Weinshilboum
Journal:  Drug Metab Dispos       Date:  2021-03-03       Impact factor: 3.922

5.  No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study.

Authors:  Paul Y Takahashi; Euijung Ryu; Suzette J Bielinski; Matthew Hathcock; Gregory D Jenkins; James R Cerhan; Janet E Olson
Journal:  Pharmgenomics Pers Med       Date:  2021-02-11

6.  Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics.

Authors:  Joel A Morales-Rosado; Kashish Goel; Lingxin Zhang; Axel Åkerblom; Saurabh Baheti; John L Black; Niclas Eriksson; Lars Wallentin; Stefan James; Robert F Storey; Shaun G Goodman; Gregory D Jenkins; Bruce W Eckloff; Suzette J Bielinski; Hugues Sicotte; Stephen Johnson; Veronique L Roger; Liewei Wang; Richard Weinshilboum; Eric W Klee; Charanjit S Rihal; Naveen L Pereira
Journal:  Cardiovasc Drugs Ther       Date:  2021-06       Impact factor: 3.947

7.  CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants.

Authors:  Lingxin Zhang; Vivekananda Sarangi; Irene Moon; Jia Yu; Duan Liu; Sandhya Devarajan; Joel M Reid; Krishna R Kalari; Liewei Wang; Richard Weinshilboum
Journal:  Clin Transl Sci       Date:  2020-03-10       Impact factor: 4.689

8.  A novel machine learning-based approach for the computational functional assessment of pharmacogenomic variants.

Authors:  Maria-Theodora Pandi; Maria Koromina; Iordanis Tsafaridis; Sotirios Patsilinakos; Evangelos Christoforou; Peter J van der Spek; George P Patrinos
Journal:  Hum Genomics       Date:  2021-08-09       Impact factor: 4.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.